Nephros (NEPH) Competitors

Nephros (NASDAQ:NEPH) and InfuSystem (NYSE:INFU) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation and dividends.

Do insiders and institutionals believe in NEPH or INFU?

41.1% of Nephros shares are owned by institutional investors. Comparatively, 71.1% of InfuSystem shares are owned by institutional investors. 6.7% of Nephros shares are owned by company insiders. Comparatively, 11.4% of InfuSystem shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Which has more volatility & risk, NEPH or INFU?

Nephros has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Comparatively, InfuSystem has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500.

Which has preferable earnings and valuation, NEPH or INFU?

InfuSystem has higher revenue and earnings than Nephros. Nephros is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nephros	$14.16M	3.09	$70K	$0.12	34.42
InfuSystem	$139.89M	1.37	$870K	$0.23	40.83

Do analysts rate NEPH or INFU?

Nephros currently has a consensus target price of $5.50, indicating a potential upside of 33.17%. InfuSystem has a consensus target price of $12.50, indicating a potential upside of 33.12%. Given Nephros' higher possible upside, research analysts clearly believe Nephros is more favorable than InfuSystem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nephros	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
InfuSystem	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	3 Strong Buy rating(s)	4.00

Is NEPH or INFU more profitable?

Nephros has a net margin of 7.95% compared to InfuSystem's net margin of 1.12%. Nephros' return on equity of 14.89% beat InfuSystem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nephros	7.95%	14.89%	11.64%
InfuSystem	1.12%	2.78%	1.41%

Does the media prefer NEPH or INFU?

In the previous week, InfuSystem had 6 more articles in the media than Nephros. MarketBeat recorded 10 mentions for InfuSystem and 4 mentions for Nephros. Nephros' average media sentiment score of 1.07 beat InfuSystem's score of 0.68 indicating that Nephros is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nephros	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
InfuSystem	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

InfuSystem beats Nephros on 10 of the 17 factors compared between the two stocks.